CBLL · Ceribell, Inc.
Market Cap
$910.71M
Shares
38.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.73
Open$23.40
Day$23.32–23.76
52W close$10.92–24.89
Avg vol 30d409K
Short int2.1M · 5.5% float · 4.2d
Short vol27%
Last earningsAug 10, 2026
DataOct 2024–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+18%
above
RSI (14)
67
neutral
MACD trend
Negative
52-week position
92%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+34%
trailing
6-month return
+30%
trailing
YTD return
+8%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +16 funds added
Insider flow
Distributing
Net -$4.7M over 90 days · 100% sells
Short interest
Rising
5.48% of float · ▲ +4.2% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
123 holders — near 1-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
88%
expanding
EPS growth
+57%
Y/Y
Free cash flow
$-41.6M
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 10, 2026
Total revenue
· full year 2026
Initiated
$114M – $117M
prior FY $89.06M
midpoint +29.7% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Revenue
· full-year 2025
$87M – $89M
Guided vs delivered
· last 2 settled
Revenue guidance
full year 2025
guided $83M – $87M
$89.06M
Beat +4.8%
Revenue
full year 2024
guided $64.2M – $64.7M
$65.44M
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+18%
Bullish
RSI (14)
67
Neutral
MACD trend
Negative
Bearish
52-week position
92%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +16 funds added
Insider flow
Distributing
Net -$4.7M over 90 days · 100% sells
Short interest
Rising
5.48% of float · ▲ +4.2% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
123 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $24 · 92%
Range high $25
vs 200-day avg +22%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -$9.82M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA loss non-GAAP | $9.8M | Q2 2026 | — |
|
|
|||
| EBITDA (Non-GAAP) non-GAAP | -$19.74M | the three months ended June 30, 2026 filing | — |
| Gross margin | 92% | Q2 2026 | — |
| Total active accounts | 712 | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBLL
this stock
Ceribell, Inc.
|
$910.71M | +8.2% | +36.1% | — | 5.5% |
|
ABT
Abbott Laboratories
|
$195.90B | -10.2% | +5.7% | 31.5 | 1.2% |
|
SYK
Stryker Corp
|
$127.12B | -5.9% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$115.17B | -5.0% | +8.4% | 24.1 | 1.1% |
|
BSX
Boston Scientific Corp
|
$67.88B | -50.9% | +12.5% | 19.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBLL | -1.9% | +34.1% | +29.8% | +34.1% | +8.2% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -2.4% | +31.2% | +16.4% | +31.2% | -4.6% |
Key facts
CIK
1861107
CUSIP
15678C102
13F (30d)
106 filings
104 filers
Visit website
Investor relations